Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

The phosphatidylinositol-3-kinase (PI3K) pathway plays a crucial role in cell growth and survival and is activated in various cancers. Multiple components of the pathway are frequently targeted by ...

Despite these differences, the authors found that chemotaxis and electrotaxis share a dependence on similar intracellular signaling molecules, most notably the phosphoinositide 3-kinase (PI3K ...

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth ...

The PIK3CA gene, which encodes the p110α subunit of phosphoinositide 3-kinase (PI3K), is among the most frequently mutated oncogenes in cancer. These mutations drive tumor progression ...

Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA highlighting the role of exosomal RNA (exRNA) in head and neck cancers (HNCs).

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...

Cellular reprogramming is an intrinsic evolutionary trait to constantly promote adaptations that confer survival advantage.

Researchers from Tokyo University of Science uncover cellular and molecular mechanisms underlying the antidepressant-like effects of the delta opioid receptor agonists, paving the way for its ...

A combination, triplet therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...